@OncoKB

MSK's precision oncology knowledge base w/ information about the effects & clinical implications of individual cancer gene alterations. Partially FDA-recognized

oncokb.org
Joined May 2016
  • Tweets152
  • Following0
  • Followers1.2K
65Media
Include

Only show posts containing:

Exclude

Hide posts containing:

Time range
-
Minimum likes
We are no longer posting updates here. To follow our data releases and see what's new, connect with us over on LinkedIn! ✌️ See you there
1
401
OncoKB™ retweeted
OncoKB™@OncoKB17 Oct 2024
Join OncoKB Nov 19-23 at AMP 2024 in Vancouver! Stop by Booth 1421 to meet @HongxinZhang and @ritikakundra10, explore our latest developments & learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB! #AMPath24
3
1
5
1,161
New OncoKB data release v4.22: ROS1 G2032R & L2086F L3A and LR2 in NSCLC. SMARCA4 onc mts L3A in NSCLC and esophageal adenocarcinoma. Amivantamab+Chemo added to EGFR ex19 inframe-del & L858R L1 in NSCLC. Inavolisib+Palb+Fulv added to PIK3CA onc mts L1 in breast cancer. And more!
4
448
Join OncoKB Nov 19-23 at AMP 2024 in Vancouver! Stop by Booth 1421 to meet @HongxinZhang and @ritikakundra10, explore our latest developments & learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB! #AMPath24
3
1
5
1,161
ALK F1174L/C, F1245Y/V & R1275Q/L L3A in neuroblastoma. MET H1094Y & F1200I L3A in NSCLC. MET N1100S, V1092I, H1106D, R1170Q & M1250T L4 in NSCLC. Promotion of Amivantamab + Lazertinib from L3A to L1 in EGFR L858R and ex19 inframe dels in NSCLC. 8 new genes. And more!
2
349
New OncoKB data release v4.20 IDH1 R132 & IDH2 R172 L1 in astrocytoma & oligodendroglioma w/ Vorasidenib. Inavolisib L3A in PIK3CA onc mts in breast cancer. Removal of H3B-8800. CCNE1 amp, FBXW7 & PPP2R1A mts L3A in endo and ovarian cancer w/ Lunresertib+Camonsertib. And more!
3
6
1,009
New OncoKB data release v4.18: KRAS G12C promoted to L1 in CRC w/ adagrasib + cetuximab. Osimertinib + chemo added as L1 in EGFR L858R & ex19del in NSCLC. Repotrectinib promoted to L1 in NTRK fusions in solid tumors. 5 new genes. And much more!
1
9
727
New OncoKB data release v4.17: POLE/D1 exo dom mts and MSI-H L2 in CRC and SBC w/ pembro, nivo, ipi+nivo & dostar. MTAP del L3A in solid tumors w/ AMG193 & MRTX1719. ALK G1202R & L1196M L2 in NSCLC w/ lorl. Mobocertinib removal from L1 EGFR exon 20 in-frame ins in NSCLC & more!
3
6
1,125
Join us May 31-June 4 at the ASCO 2024 Annual meeting in Chicago at Booth # 37106 to meet our team, explore our latest developments and learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB licensing and content!
2
1
4
3,710
New OncoKB data release v4.16: Release of CDx page incl biomarker, cancer type, drug & specimen type. BRAF fusions & V600 mts L1 in LGG. ERBB2 amp L2 in salivary gland cancer & L3A in solid tumors, the latter following FDA-approval of T-DXd for HER2+ (IHC3+) tumors + 7 new genes
1
6
18
1,494
New release my @OncoKB people! Major updates: Removal of FGFR2-fusion+ #bladdercancer as L1 based on @US_FDA amendmt to erdafitinib label +MDM2 amplification➡️L3A in intimal-& lipo-sarcomas based on compelling clinical activity of MDM2-p53 antag milademetan&brigimadlin resp
6
22
2,137
New @OncoKB release people! AKT1 (& PIK3CA & PTEN onc mut) = Level 1 w/ pan-AKT inh capivasertib + fulvestrant @US_FDA apprval for pts w/ breast cancer 🤔drug showed activity in overall ER+/HER2- popn +Reprotrectinib apprvd in ROS1+ NSCLC w/ activity against solvt front resist
4
12
1,005
If you want to explore more about OncoKB, please join us at #amp2023 #AMPath2023 booth #928
Michael Berger@MFBerger116 Nov 2023
Packed house at #AMPath23 to see 🌟 lead scientist @CDebyaniPhD present @OncoKB, the @US_FDA recognized cancer knowledge base, bringing precision oncology to patients at @MSKCancerCenter and now around the 🌏
2
489
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you.
135
Addition of 4 New Genes: CTNNA1, FGF10, FGF14, HSP90AA1
1
150
Updated Therapeutic Implications Niraparib + Abiraterone Acetate + Prednisone added as a treatment for BRCA1/2 oncogenic mutations in prostate cancer, solidifying its Level 1 evidence based on latest FDA-approval. fda.gov/drugs/resources-info…

FDA approves niraparib and abiraterone acetate plus prednisone for BRC

FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer

fda.gov
1
53
Updated Therapeutic Implications Ivosidenib’s evidence level for treating IDH1 R132 mutant Myelodysplastic Syndromes has been elevated from 3B to 1, post FDA-approval. fda.gov/drugs/resources-info…
1
58
New OncoKB data release v4.11
1
1
3
385
Dr. @CDebyaniPhD is going to present OncoKB during the plenary session "Clinical Grade Knowledge Bases for Genomic Actionability" (Thu 11/16, 1:15pm MST).
1
5
350
Join us at the #AMP2023 to meet the team and explore the latest developments @ booth#928 ! Our team members @HongxinZhang and @ritikakundra10 will answer all your licensing and content questions! #AMP2023 #OncoKB #PrecisionMedicine #MSKCC
1
3
6
538
Load more